Literature DB >> 3147522

A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis.

J W Boslego1, C B Hicks, R Greenup, R J Thomas, H A Wiener, J Ciak, E C Tramont.   

Abstract

One hundred fourteen men with uncomplicated urethritis were randomized to receive 1 week of therapy with either doxycycline (100 mg twice daily) or ofloxacin (300 mg twice daily). Of the 109 men completing the post-treatment visit, 56 received ofloxacin and 52 (93%) were clinically cured. Forty four (83%) of the 53 men treated with doxycycline were cured. All 30 patients with gonorrhea (including three with penicillinase-producing Neisseria gonorrhoeae [PPNG] isolates) who were treated with ofloxacin became culture-negative, as compared with 32 of 34 patients receiving doxycycline. In contrast, three of 18 patients with Chlamydia trachomatis were microbiologic failures after ofloxacin therapy, while all ten treated with doxycycline were cured. Adverse effects of both treatment regimens were generally mild, and compliance was excellent except for one patient receiving doxycycline. These results show that ofloxacin, in a dosage of 300 mg taken orally twice daily for seven days, is an effective treatment for uncomplicated urethritis in men but may not reliably cure chlamydial infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147522     DOI: 10.1097/00007435-198810000-00002

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  12 in total

1.  Comparison of ofloxacin with oxytetracycline in the treatment of non-gonococcal urethritis in men.

Authors:  V Battu; J T Arumainayagam; A N McClean
Journal:  Genitourin Med       Date:  1991-12

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Oral ciprofloxacin versus ceftriaxone for the treatment of urethritis from resistant Neisseria gonorrhoeae in Zambia.

Authors:  J P Bryan; S K Hira; W Brady; N Luo; C Mwale; G Mpoko; R Krieg; E Siwiwaliondo; C Reichart; C Waters
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 4.  Chlamydia (uncomplicated, genital).

Authors:  Paddy Horner
Journal:  BMJ Clin Evid       Date:  2010-04-22

Review 5.  Chlamydia (uncomplicated, genital).

Authors:  Megan Crofts; Paddy Horner
Journal:  BMJ Clin Evid       Date:  2015-04-16

6.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

7.  Ofloxacin susceptibilities of 5,667 Neisseria gonorrhoeae strains isolated in Hong Kong.

Authors:  K M Kam; K K Lo; C F Lai; Y S Lee; C B Chan
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 8.  Chlamydia (uncomplicated, genital).

Authors:  Paddy Horner
Journal:  BMJ Clin Evid       Date:  2008-06-23

9.  Detection of quinolone-resistant Neisseria gonorrhoeae.

Authors:  K M Kam; P W Wong; M M Cheung; N K Ho
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

10.  Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women.

Authors:  Carol Páez-Canro; Juan Pablo Alzate; Lina M González; Jorge Andres Rubio-Romero; Anne Lethaby; Hernando G Gaitán
Journal:  Cochrane Database Syst Rev       Date:  2019-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.